Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in Sweden / NCT06906276
Recruiting Observational

Brain Activity During Complex Walking in People With Atypical Parkinsonian Syndromes

NCT06906276 · tracked via the Priya Life Science Sweden tracker
Sponsor
Karolinska Institutet
Phase
Observational
Started
2025-03-14
Last updated
2025-07-08

Condition(s) studied

Gait Disorders, NeurologicAtypical Parkinson DiseasefNIRSAging

Investigational drug(s) / intervention(s)

Assessment of brain activity with fNIRS and behavioural assessments (motor, motor-cognitive and cognitive) during three complex walking conditions.

Assessment of brain activity with fNIRS and behavioural assessments (motor, motor-cognitive and cognitive) during three complex walking conditions.: Dual-task walking with the auditory stroop task. Navigational walking - a course consisting of a distribution of 45 and 90 degrees turns to the left and right Navigational and dual-task walking (condition 1 and 2 together)

Study summary

Every-day life means being part of a complex environment and performing complex tasks that usually involve a combination of motor and cognitive skills. However, the process of aging or the sequelae of neurological diseases such as atypical Parkinson's disease (APD) compromises motor-cognitive interaction necessary for an independent lifestyle. While motor-cognitive performance has been identified as an important goal for sustained health across different clinical populations, little is known about underlying brain function leading to these difficulties and how to best target these motor-cognitive difficulties in the context of rehabilitation and exercise interventions.

The challenge of improving treatments of motor-cognitive difficulties (such as dual-tasking and navigation) is daunting, and an important step is arriving at a method that accurately portrays these impairments in an ecologically valid state. The investigators aim therefore to explore brain function during complex walking in healthy and APD by investigating the effects of age and neurological disease on motor-cognitive performance and its neural correlates during three conditions of complex walking (dual-task walking, navigation and a combination of both) using non-invasive measures of brain activity (functional near infrared spectrometry, fNIRS) and advanced gait analysis in real time in older healthy adults and people with APD.

Eligibility

Sex
ALL
Min age
—
Max age
—
Healthy volunteers
No
Inclusion Criteria: * clinical diagnosis of PSP according to Movement Disorder Society (MDS) (2017) or * MSA according to MDS criteria (2022) * the ability to walk with or without a mobility device for ≤5 minutes continuously Exclusion Criteria: * cognitive difficulties affecting the ability to understand and/or follow verbal/written - instructions * severe freezing of gait * Severe hearing or visual impairments that affect participation in the assessments * Other neurological diseases * Other diseases that can affect gait or balance.

Primary outcome measure(s)

  • Functional near infrared spectrometry (fNIRS) — Baseline
    The measurement of changes in concentration of HbO and HHb in the prefrontal cortex will be assessed using a NIRSPORT 2 (NIRx Medizintechnik, Berlin, Germany) device.
  • Gait performance during all conditions — Baseline
    Gait variables such as stride time and/or velocity will be analyzed with the APDM mobility system.
  • Dual-task performance-reaction time — Baseline
    Cognitive performance of the dual task will be assessed as errors in the response to the Auditory Stroop task.

Trial sites (1)

FacilityCityRegionStatus
Karolinska Institutet Solna Solna Recruiting

More Karolinska Institutet trials in Sweden

Effects of Individual Tailored Physical Exercise in Patients With POTS After COVID-19 - a Randomized Controlled Study Active, not recruiting
Implementation of Evidence-based Guidelines for Assessment and Counseling of Patients With Neck and Back Pain in Health Care Centers Starting soon
Single Nuclei Sequencing in Human Skeletal Muscle After Unloading Enrolling by invitation
Validation of a Novel Smartphone-based Method for Heart Rhythm Monitoring in the Home Environment Active, not recruiting
Omission of Axillary Lymph Node Dissection in Case of Tumor Spread to Lymph Nodes in the Armpit in Breast Cancer Recruiting

Other trials for the same condition

Unsteady Gait in Older People May be a Common and Treatable Neurological Disease Associated With Increased Mortality Enrolling by invitation
Walking and Thinking - Brain Activity During Complex Walking in Stroke Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06906276 on ClinicalTrials.gov ↗ ← All trials in Sweden